Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsRanbaxylaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Buy UltraTech Cement around Rs 1350- 1400: Malkan

      Buy UltraTech Cement around Rs 1350- 1400: Malkan

      Buy UltraTech Cement around Rs 1350- 1400, says Vishal B Malkan, CMT, www.malkansview.com.

    • Bull's Eye: Buy Voltas, Alfa Laval, Ranbaxy, short HDFC

      Bull's Eye: Buy Voltas, Alfa Laval, Ranbaxy, short HDFC

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • PN Vijay`s view on Ranbaxy Labs

      PN Vijay`s view on Ranbaxy Labs

      PN Vijay, Portfolio Manager, askpnvijay.com advice investors to avoid Ranbaxy Labs at this point of time.

    • Buy Ranbaxy, says Sudarshan Sukhani

      Buy Ranbaxy, says Sudarshan Sukhani

      Buy Ranbaxy, says Sudarshan Sukhani of s2analytics.com.

    • Buy Ranbaxy: Sukhani

      Buy Ranbaxy: Sukhani

      Sudarshan Sukhani of s2analytics is of the view that one can buy Ranbaxy for day trading.

    • PN Vijay`s view on BHEL, Ranbaxy Labs

      PN Vijay`s view on BHEL, Ranbaxy Labs

      PN Vijay, Portfolio Manager, www.askpnvijay.com shares his view on BHEL and Ranbaxy Labs.

    • Buy Ranbaxy for trading: Baliga

      Buy Ranbaxy for trading: Baliga

      Buy Ranbaxy at lower levels with trading perspective, says Ambareesh Baliga of Way2wealth.

    • Bull's Eye: Pick Tata Motors, Yes Bank; short Ranbaxy

      Bull's Eye: Pick Tata Motors, Yes Bank; short Ranbaxy

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Ranbaxy Labs may slip to Rs 389- 388: Sukhani

      Ranbaxy Labs may slip to Rs 389- 388: Sukhani

      Ranbaxy Labs may slip to Rs 389- 388, says Sudarshan Sukhani, s2analytics.com.

    • More upside seen in GVK Power, says Sukhani

      More upside seen in GVK Power, says Sukhani

      More upside seen in GVK Power, says Sudarshan Sukhani of s2analytics.com.

    • Ranbaxy Labs may test Rs 515, says Devang Mehta

      Ranbaxy Labs may test Rs 515, says Devang Mehta

      Ranbaxy Labs may test Rs 515 in next 1 -1.5 years, says Devang Mehta, Anand Rathi Financial Services.

    • Buy Ranbaxy Labs, says Sudarshan Sukhani

      Buy Ranbaxy Labs, says Sudarshan Sukhani

      Sudarshan Sukhani, s2analytics.com advice investors to buy Ranbaxy Labs at current levels.

    • Stay away from HOEC, says Sudarshan Sukhani

      Stay away from HOEC, says Sudarshan Sukhani

      Sudarshan Sukhani, s2analytics.com advice investors to stay away from HOEC.

    • Ranbaxy Labs has short term target of Rs 410- 415: Sukhani

      Ranbaxy Labs has short term target of Rs 410- 415: Sukhani

      Ranbaxy Labs has short term target of Rs 410- 415, says Sudarshan Sukhani of s2analytics.com.

    • Sell Ranbaxy: Sudarshan Sukhani

      Sell Ranbaxy: Sudarshan Sukhani

      Sell Ranbaxy, says Sudarshan Sukhani of s2analytics.com.

    • Below Rs 690, ICICI Bank may test Rs 660-630: Manghnani

      Below Rs 690, ICICI Bank may test Rs 660-630: Manghnani

      Below Rs 690, ICICI Bank may test Rs 660-630, says Anil Manghnani, Modern Shares & Stock Brokers.

    • SP Tulsian positive on Cox & Kings

      SP Tulsian positive on Cox & Kings

      SP Tulsian, sptulsian.com is positive on Cox & Kings.

    • Super Six: Manas, Vishal, Rajesh on their top picks

      Super Six: Manas, Vishal, Rajesh on their top picks

      On CNBC-TV18's show Super Six, market gurus Manas Jaiswal, Technical Analyst, manasjaiswal.com, Vishal Kshatriya, Sr. Derivative and Technical Analyst, Edelweiss and Rajesh Jain, EVP Reatail Research, Religare Sec place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Ranbaxy may test Rs 420-430: Bhamre

      Ranbaxy may test Rs 420-430: Bhamre

      Ranbaxy may test Rs 420-430, says Siddharth Bhamre, Angel Broking.

    • Sell Ranbaxy Laboratories on rally: Sukhani

      Sell Ranbaxy Laboratories on rally: Sukhani

      Sudarshan Sukhani, s2analytics.com is of the view that one can sell Ranbaxy Laboratories on rally.

    • Stay away from Ranbaxy Labs: PN Vijay

      Stay away from Ranbaxy Labs: PN Vijay

      PN Vijay, Portfolio Manager feels that one should stay away from Ranbaxy Labs.

    • Buy Ranbaxy, says Kunal Saraogi

      Buy Ranbaxy, says Kunal Saraogi

      Kunal Saraogi of Equityrush feels that one should buy Ranbaxy.

    • Bull's Eye: 12 stock ideas to liven up your trade

      Bull's Eye: 12 stock ideas to liven up your trade

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Devangshu Dutta's view on Reliance

      Devangshu Dutta's view on Reliance

      Devangshu Dutta, Consulting Editor, Outlook share his view on Reliance Industries.

    • Sell Ranbaxy, says Sudarshan Sukhani

      Sell Ranbaxy, says Sudarshan Sukhani

      Sell Ranbaxy, says Sudarshan Sukhani of s2analytics.com.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347